Topic

Articles

The acquisition adds a potential rare disease asset to Sanofi’s alpha-1 antitrypsin deficiency pipeline.

Sanofi to Aquire Inhibrx for $1.7 Billion

The acquisition will give Novartis full rights to CALY-002, Calypso’s lead product candidate.

Novartis Acquires Calypso Biotech for up to $425 Million

Felicity Thomas is Associate Editorial Director of Pharmaceutical Technology, Pharmaceutical Technology Europe, BioPharm International.

The acquisition marks a pivotal expansion for the company into the US market. 

Bora Pharmaceuticals Fuels Global Expansion with Acquisition in US

Feliza Mirasol is the science editor for 

Through the acquisition of Harpoon Therapeutics, Merck will gain an investigational delta-like ligand 3-targeting T-cell engager under development for cancer treatment.

Merck to Acquire Harpoon Therapeutics in Deal Valued at $680 Million

Cherwell Laboratories’ cleanroom microbiology solutions will join AnalytiChem’s group of seven companies across Europe, North America, and Australia.

Cherwell Joins AnalytiChem Group

In a deal worth up to $1.4 billion, GSK aims to acquire Aiolos Bio and gain an expanded pipeline of biologic-based respiratory therapeutic candidates. 

GSK to Acquire Aiolos Bio, Expands Respiratory Portfolio

Roche will acquire select parts of the LumiraDx group related to that company’s point-of-care technology, which integrates multiple tests on a single instrument. 

Roche to Acquire Point-of-Care Technology from LumiraDx in $350 Million Deal

AstraZeneca’s acquisition of Gracell includes a clinical-stage autologous cell therapy targeting hematologic malignancies and autoimmune diseases and a proprietary manufacturing platform.

AstraZeneca Poised to Acquire Cell Therapy Developer, Gracell, in Deal Valued at $1.2 Billion

With the acquisition, AstraZeneca will gain a potential RSV and hMPV combination vaccine.

AstraZeneca to Acquire Icosavax in Deal Valued at Approximately $1.1 Billion 

AbbVie’s proposed acquisition of ImmunoGen is expected to accelerate AbbVie's entry into the commercial market for ovarian cancer and includes ImmunoGen’s flagship cancer therapy, ELAHERE (mirvetuximab soravtansine-gynx).

Mergers and Acquisitions